DNA N⁶-methyladenine modification in hypertension

Area of Science:

• Epigenetics
• Molecular Biology
• Cardiovascular Research

Background:

• DNA methylation is implicated in essential hypertension pathogenesis.
• DNA N6-methyladenine (6mA) is a novel adenine modification in human tissues, with its role in hypertension unexplored.

Purpose of the Study:

• To investigate the role of DNA N6-methyladenine (6mA) in the development of essential hypertension.
• To explore the regulatory mechanisms involving ALKBH1 and its impact on vascular cells.

Main Methods:

• Quantification of global 6mA DNA levels in leukocytes from hypertensive patients and controls.
• Analysis of ALKBH1 (AlkB homolog 1) levels in human leukocytes and in hypertension mouse/rat models.
• In vitro studies involving knockdown of ALKBH1 in vascular smooth muscle cells.
• Investigation of the interaction between ALKBH1, 6mA, and HIF1α.

Main Results:

• Global 6mA DNA levels were significantly reduced in hypertensive patients and normalized post-treatment.
• Leukocyte 6mA levels correlated with age, systolic blood pressure, and lipid profiles.
• Elevated ALKBH1 levels were observed in hypertension models, mediating 6mA changes.
• ALKBH1 knockdown inhibited angiotensin II-induced vascular smooth muscle cell changes and HIF1α regulation.

Conclusions:

• DNA N6-methyladenine (6mA) modification, regulated by ALKBH1, plays a significant epigenetic role in hypertension development.
• ALKBH1-6mA pathway influences angiotensin II-induced vascular remodeling via HIF1α.
• Findings suggest potential for ALKBH1-6mA in hypertension diagnosis and therapeutic strategies.